CTLA4 and glioblastoma: Garg et al. found that predictive biomarkers of responsiveness to immune-checkpoint inhibitors in glioblastoma (GBM) exhibited inconsistent patterns among patients, predicting either resistance or susceptibility to therapeutic targeting of CTLA-4 or IDO1 (76).